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Abstract	
Purpose:	The	use	of	cumulative	measures	of	exposure	to	raised	HIV	viral	load	(viremia	copy-years)	is	an	increasingly	common	in	HIV	prevention	and	treatment	epidemiology	due	to	the	high	biological	plausibility.	We	sought	to	estimate	the	magnitude	and	direction	of	bias	in	a	cumulative	measure	of	viremia	caused	by	different	frequency	of	sampling	and	duration	of	follow-up.		
Methods:	We	simulated	longitudinal	viral	load	measures	and	reanalysed	cohort	study	datasets	with	longitudinal	viral	load	measurements	under	different	sampling	strategies	to	estimate	cumulative	viremia.		
Results:	In	both	simulated	and	observed	data,	estimates	of	cumulative	viremia	by	the	trapezoidal	rule	show	systematic	upward	bias	when	there	are	fewer	sampling	time	points	and/or	increased	duration	between	sampling	time	points,	compared	to	estimation	of	full	time	series.	Absolute	values	of	cumulative	viremia	vary	appreciably	by	the	patterns	of	viral	load	over	time,	even	after	adjustment	for	total	duration	of	follow	up.		
Conclusions:	Sampling	bias	due	to	differential		frequency	of	sampling	appears	extensive	and	of	meaningful	magnitude	in	measures	of	cumulative	viremia.	Cumulative	measures	of	viremia	should	be	used	only	in	studies	with	sufficient	frequency	of	viral	load	measures	and	always	as	relative	measures.		
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1.	Introduction	Cumulative	measures	of	exposure	are	widely	used	in	different	areas	of	epidemiologic	research	in	the	estimation	of	the	effects	associated	with	exposures	over	time	[1].	In	infectious	diseases	epidemiology,	cumulative	viral	load	(cVL),	or	viremia	copy-years,	has	been	proposed	as	an	estimate	of	the	cumulative	exposure	to	raised	HIV-RNA	viral	load	(VL)	in	individuals	infected	with	human	immunodeficiency	virus	(HIV).	This	cumulative	exposure	measure	has	high	biological	plausibility:	raised	VL	is	the	primary	marker	of	both	disease	control	and	infection	transmission	risk	[2].	In	individuals	receiving	antiretroviral	therapy	(ART),	raised	VL	is	associated	with	treatment	failure	and	poor	long-term	treatment	outcomes	[3].	Cumulative	exposure	to	raised	VL	has	been	hypothesised	as	a	potential	risk	factor,	or	predictor	of	poor	outcomes	[4-6].		cVL	appears	to	have	been	introduced	independently	by	Zoufaly	et	al.	[7]	and	Cole	et	al.	[8]	in	association	with	outcomes	related	to	the	development	of	acquired	immune	deficiency	syndrome	(AIDS).	Subsequently,	variants	of	cVL	appeared	in	use	across	a	variety	of	studies,	where	the	measure	was	often	intended	as	a	potential	risk	factor	to	predict	outcomes	such	as	all-cause	mortality	[4-6,9,10].	The	empirical	evidence	for	cVL	as	a	useful	prognostic	factor	for	long	term	outcomes	is	mixed.	While	there	is	a	biological	argument	to	be	made	that	the	cumulative	exposure	to	raised	VL	[11,	12]	could	be	predictive	of	health	outcomes,	the	empirical	measurement	of	cumulative	exposure	by	cVL	has	failed	to	demonstrate	consistent	associations.	For	example,	Cates	et	al	[13]	conclude	that	cVL	burden	prior	to	pregnancy	is	not	informative	in	a	study	of	risk	of	pregnancy	loss	among	HIV	infected	women,	but	current	VL	appears	highly	predictive.	In	a	follow	up	efficacy	study	comparing	the	antiretroviral	drugs	efavirenz	and	boosted	lopinavir,	cautious	optimism	was	expressed	towards	the	use	of	cVL	as	a	prognostic	factor	[14].	Kukoyi	et	al	[15]	found	that	a	log10	copies/mL/year	measure	to	evaluate	morbidity	outcomes	in	a	paediatric	cohort	was	predictive,	but	the	VL	measure	is	included	in	analyses	as	a	discrete	variable,	with	just	three	levels.	Kowalkowski	et	al	[16]	also	found	associations	in	sub-analyses	between	a	measure	of	cVL	and	non-AIDS	defining	malignancies,	utilising	a	complex	series	of	data	imputation	on	7-day	follow	up	windows.	Taken	together,	it	remains	unclear	if	cVL	has	greater	utility	then	current	or	most	recent	VL.		Common	concerns	related	to	cumulative	measures	of	exposure	in	epidemiology	include	time-based	dependence	of	exposure	and	the	method	of	measurement	(direct	or	indirect)	[7].	cVL	may	be	defined	as	the	area	under	the	plasma	VL	curve	and	has	been	calculated	using	copies/mL	or	log10	copies/mL.	However,	the	phrase	“under	the	curve”	is	not	precise,	as	VL	is	not	continuously	measured	over	time,	but	sampled	at	discrete	time	points,	and	therefore	the	true	individual	trajectory	is	unknown	and	the	area	must	be	approximated	using	integral	approximation	
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methods.	Some	of	the	mixed	empirical	results	in	estimating	the	association	of	cVL	to	health	outcomes	may	be	due	to	the	inconsistencies	in	estimation.	The	majority	of	analyses	estimate	cumulative	viremia	or	viral	copy-years	using	the	trapezoidal	rule,	which	sums	the	areas	between	two	successive	points	joined	by	linear	interpolation	[17].		While	it	has	been	established	that	this	method	is	scale	dependent	[18],	no	research	has	examined	the	impact	of	sampling	frequency	bias.	Here	we	estimate	the	bias	due	to	changes	in	sampling	frequency	when	estimating	cVL	by	the	trapezoidal	rule.	We	utilise	two	empirical	and	one	simulated	data	set,	each	with	repeated	VL	measures,	to	estimate	the	magnitude	and	direction	of	the	bias	in	the	estimation	of	cVL	and	make	recommendations	for	improved	usage.			
2.	Methods	
2.1	Data	sources	We	used	three	different	data	sources	to	examine	how	sampling	time	points	effect	cVL	estimation:		an	intensively	monitored	cohort	of	women	initiating	ART	[11],	a	simulated	data	set	of	longitudinal	HIV	VL	trajectories	developed	for	a	monitoring	study	[19],	and	a	random	sample	of	routine	VL	data	collected	by	the	South	African	National	Health	Laboratory	Services	(NHLS)	[20].	The	two	empirical	datasets	were	selected	to	reflect	different	types	of	data	collection,	either	under	intensive	health	research	and	follow-up	or	under	routine	care	and	with	different	expected	longitudinal	VL	trajectories	drawing	from	different	populations.	The	inclusion	of	simulated	data	provides	an	opportunity	to	evaluate	estimation	of	cVL	at	different	sampling	frequencies	against	a	known	‘truth’.		The	cohort	study	has	VL	measures	of	518	women	initiating	ART	during	pregnancy	and	followed	up	to	approximately	18	months	postpartum.	This	is	a	frequently	measured	cohort	with	a	median	of	7	VL	measures	during	the	follow	up,	which	is	much	more	frequent	than	most	routine	clinical	settings.	The	routine	monitoring	sample	includes	n	=	29,519	individuals,	who	were	not	virally	suppressed	for	the	entire	duration	of	follow-up	and	had	a	minimum	of	5	VL	measures	from	the	NHLS	data	set.	The	sample	is	extracted	from	routine	laboratory	data	comprised	of	individuals	in	ART	programmes	in	the	Western	Cape,	South	Africa.	This	routinely	collected	monitoring	data	has	either	6	or	12	months	between	VL	measures,	on	average,	following	South	African	treatment	guidelines	[21].	The	simulated	dataset	is	contributed	from	a	model	of	longitudinal	VL	trajectories	for	80	weeks	on	a	weekly	time	step	[20].	The	data	is	simulated	to	mimic	trajectories	and	conditions	of	patients	initiating	ART	during	and	contains	a	simulated	sample	of	10,000	individuals.		
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This	study	is	an	analysis	of	secondary	data	which	was	originally	collected	by	studies	carried	out	under	ethics	approval	from	the	University	of	Cape	Town	Faculty	of	Health	Sciences	Human	Research	Ethics	Committee	(HREC:	865/2016;	329/2014;	451/2012).		
2.2	Estimation	of	cVL	Log10	VL	measures	are	used	throughout	in	the	calculation	of	cVL.	cVL	is	calculated	for	each	time	series	using	the	trapezoidal	rule	which	uses	a	linear	approximation	between	successive	points	(Equation	1	and	Figure	1).	VL	measures	below	50	copies	per	mL	are	set	to	zero	to	avoid	an	increase	in	cVL	while	below	the	limit	of	detection.	In	addition	to	estimating	cVL	over	the	given	time	frame	(between	first	and	last	VL	observations,	regardless	of	total	duration	of	observation)	we	calculate	a	standardised	cVL	that	adjusts	for	individual	follow-up	time	(Equation	2).	Median	(interquartile)	range	of	the	individual	estimates	of	cVL	are	reported.		
																			
2.3	Subsampling	We	calculate	cVL	based	on	subsets	of	the	available	data	and	compare	these	estimates	to	the	cVLREF,	which	uses	every	data	point	in	the	full	time	series.	We	use	two	different	subsampling	strategies:	a)	random	subsample	to	a	set	number	of	VL	measures	(n=2	-	5),	ensuring	that	the	first	and	last	VL	measure	per	individual	are	always	retained	to	ensure	consistency	with	total	follow	up	time	and	b)	sampling	based	on	average	interval	between	VL	measures,	retaining	the	first	and	last	VL	measure	per	individual.	Median	and	interquartile	ranges	for	estimated	cVL	are	provided,	as	well	as	the	percent	change	compared	to	cVLREF.	This	estimate	reflects	both	the	viremia	and	duration	of	follow	up	of	individuals	in	the	respective	data	sets.	A	follow-up	standardised	measure	is	also	calculated	and	reported	in	order	to	reduce	the	dependence	on	the	individual's	total	duration	of	follow-up.	This	measure	is	analogous	to	the	viral	copy-year.	The	cVLFU	is	calculated	using	all	available	VL	measures,	and	then	individually	standardised	for	total	follow-up	time.	Cohort	viral	load	trajectories	were	visualised	using	generalised	additive	model	smoothing	with	a	natural	b-spline.		
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Figure	1:	Schematic	of	plasma	VL	versus	time	for	one	profile	under	two	different	monitoring	schemes.	Profile	A	(top)	has	been	measured	at	4	time	points	and	Profile	B	(bottom)	at	only	three	time	points.	In	each	profile	the	resulting	estimated	cVL	is	represented	by	the	shaded	region.			
3	Results	Characteristics	of	the	three	data	sets	can	be	found	in	Table	1.	The	data	sources	vary	over	indicators	including	the	median	number	of	VL	measures	available	per	individual,	the	median	time	between	VL	measures	and	the	total	duration	of	follow	up.	The	median	duration	between	VL	measures	varies	from	a	low	of	one	week	(simulated	data)	to	a	high	of	five	months	(routine	laboratory	data).	The	median	VL	measures	available	per	person	is	7	(IQR:	5-9),	7	(IQR:	6-9)	and	21	(IQR:	15-26)	in	the	cohort,	routine	monitoring	and	in	the	simulated	data	sets	respectively.	
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The	duration	of	follow	up	is	the	longest	in	the	routine	data,	at	a	median	of	3.8	years	(IQR:	2.7-5.2	years)	and	shortest	in	the	simulated	VL	data	at	0.4	years	(IQR:	0.3,	0.5	years).		
Table	1:	Summary	characteristics	of	data	sets	used	for	estimation	of	cVL	
	 Simulated	data	n	=10,000	 Cohort	n	=	518	 Routine	laboratory	n	=	29,519	VL	measures	(N)	 601,070	 3,519	 253,503	Proportion	VL	<	50		 0.17	 0.66	 0.39	Proportion	VL	50-1000	 0.67	 0.16	 0.188	Proportion	VL	>1000	 0.16	 0.19	 0.43	
VL	measures	available	per	individual		median	(Q1,	Q3)	 61	(55,	65)	 7	(5,	9)	 7	(6,	9)	Follow-up	duration	per	individual	(years)	median	(Q1,	Q3)	 1.2	(1.0,	1.2)	 1.1	(0.6,	1.4)	 3.8	(2.7,	5.2)	Follow-up	duration	per	individual	(weeks)	median	(Q1,	Q3)	 60.0	(54.0,	64.0)	 59.6	(33.6,	71.6)	 199.7	(142.4,	271.7)	Median	time	between	observations	per	individual		median	(Q1,	Q3)	(weeks)	 1.0	(1.0,1.0)	 7.1	(4.9,	13.0)	 19.8	(4.0,	33.7)	
Total	person-years	 11,367	 548	 117,279		
The	cVLREF	is	calculated	using	all	available	VL	measures	in	each	data	set	and	represents	the	most	accurate	possible	measure	of	cVL	(Table	2).	The	median	cVL	measure	is	0.49	log10	copies/mL	years	(IQR:	0.20-0.97	log10	copies/mL	years)	using	the	cohort	data,	7.39	log10	copies/mL	years	(IQR:	4.55-11.41	log10	copies/mL	years)	in	the	routine	monitoring	laboratory	data,	and	2.08	log10	copies/mL	years	(IQR:	1.84-2.72	log10	copies/mL	years)	in	the	simulated	data.	The	median	standardised	cVL	measure	in	the	cohort	is	0.50		log10	copies/mL	year	(IQR:	0.23-1.34	log10	copies/mL	year),	in	the	routine	laboratory	data	2.10	log10	copies/mL	year	(IQR:	1.29-3.12	log10	copies/mL	year),	and	in	the	simulated	data	2.09	log10	copies/mL	year	(IQR:	1.57-2.24	log10	copies/mL	year).		
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Table	2:	Estimated	cVL	using	complete	time	series	per	individual	(bold)	and	using	different	random	sub-samples	of	observations.	Estimates	given	as	median	(IQR)	of	individual	cVL	calculations	and	as	relative	percent	change	between	median	cVL	levels.	Values	given	as	median	(Q1,	Q3)	unless	specified.	
	 Simulated	data	 Cohort	 Routine	laboratory	
Reference	cVL		(cVLREF)	 2.08	(1.84,	2.72)	 0.49	(0.20,	0.97)	 7.39	(4.55,	11.41)	cVL2	subsample:	N	=	2	VL/person	(first	and	last	observations)	 2.99	(2.44,	3.71)	 2.17	(0.93,	3.18)	 7.52	(3.98,	11.82)																			Percent	change	from	cVLREF	 +44%	 +344%	 +2%	cVL3	subsample:	N	=	3	VL/person	 2.62	(2.08,	3.24)	 1.05	(0.53,	1.93)	 7.69	(4.35,	11.94)																			Percent	change	from	cVLREF	 +26%	 +115%	 +4%	cVL4	subsample:	N	=	4	VL/person	 2.48	(1.98,	3.06)	 0.79	(0.42,	1.53)	 7.58	(4.43,	11.90)																			Percent	change	from	cVLREF	 +19%	 +62%	 +3%	cVL5	subsample:	N	=	5	VL/person	 2.41	(1.94,	2.95)	 0.73	(0.37,	1.42)	 7.52	(4.46,	11.82)																			Percent	change	from	cVLREF	 +16%	 +50%	 +2%	
Standardised	reference	cVL	
(cVLFUD	=	cVLREF	/	FUD_yrs)	 2.09	(1.57,	2.24)	 0.50	(0.23,	1.34)	 2.1	(1.29,	3.12)	cVL2	subsample:	N	=	2	VL/person	(first	and	last	observations)	 2.65	(2.19,	3.22)	 2	(1.54,	2.50)	 2.21	(1.27,	3.14)	
																		Percent	change	from	cVLFUD	 +27%	 +301%	 +5%	cVL3	subsample:	N	=	3	VL/person	 2.34	(1.86,	2.84)	 1.24	(0.59,	1.74)	 2.21	(1.35,	3.21)																			Percent	change	from	cVLFUD	 +12%	 +149%	 +5%	cVL4	subsample:	N	=	4	VL/person	 2.24	(1.78,	2.65)	 0.79	(0.37,	1.50)		 2.18	(1.33,	3.21)																			Percent	change	from	cVLFUD	 +7%	 +59%	 +4%	cVL5	subsample:	N	=	5	VL/person	 2.20	(1.72,	2.55)	 	0.59	(0.30,	1.26)	 2.15	(1.32,	3.19)																			Percent	change	from	cVLFUD	 +5%	 +18%	 +2%		
Meaningfully	large	differences	in	estimated	cVL	are	found	between	cVLREF	compared	to	random	subsamples	with	reduced	numbers	of	observations	(Table	2).	There	is	a	significant	and	meaningful	bias	towards	overestimation,	ranging	from	+50%	to	+344%	change	compared	to	cVL	reference	in	the	cohort,	and	a	+16%	to	+44%	change	from	reference	in	the	simulated	data,	both	of	which	reflect	short	duration	(<2	years)	follow-up.	The	routine	monitoring	data	demonstrates	a	different	pattern	of	bias	of	small	but	consistent	overestimation	of	between	+3%	to	+4%	from	reference	cVL.	This	consistency	is	partially	reflective	of	the	high	proportion	(39%)	of	observations	that	are	<50	copies/mL	and	the	overestimation	increases	when	the	proportion	of	
		
9	
VL	measures	<50	copies/mL	decreases.	Use	of	the	follow-up	standardised	reference	measure	reduces	the	extent	of	the	bias	in	the	cohort	and	simulation	data,	where	it	ranges	from	+18%	to	+301%	(cohort)	and	+5%	to	+27%	(simulation).	In	the	routine	laboratory	data	the	change	from	reference	remained	consistently	positive	and	ranged	from	+2%	to	+5%.	In	general,	the	different	subsamples	give	estimates	further	away	from	the	reference	measure	as	the	number	of	subsamples	decreases	(Table	2).		
	
Figure	2:	Smoothed	sample	trajectories	for	each	data	sets	under	sub-sampling.	Top	panel	is	linear	fit	and	bottom	panel	fit	by	generalised	additive	models	(GAMs)	using	all	VL	measures	available	in	each	of	the	available	(subsampled)	data	sets.			
		
10	
Figure	2	shows	smoothed	trajectories	for	subsamples,	under	linear	and	generalised	additive	model	smoothing,	to	aid	in	understanding	the	mean	data	trends	under	each	of	the	subsampling	strategies.	Specifically	we	see	that	both	the	linear	and	spline	fits	show	the	2	VL	subsample	superior	to	the	fits	of	all	other	samples,	including	the	complete	data	case	in	the	cohort	and	simulated	data,	but	this	is	reversed	in	the	routine	laboratory	data.		When	evaluating	the	subsamples	where	sampling	was	based	on	increasing	the	mean	duration	between	VL	measures,	there	was	an	increasing	positive	bias	in	the	estimation	of	cVL,	from	+7%	to	+20%	as	the	duration	between	samples	increases	from	4	weeks	to	24	weeks.	The	empirical	cohort	data	demonstrates	the	same	trend,	but	with	much	larger	bias,	ranging	from	+36%	at	4	weeks	minimum	duration	to	+335%	at	24	weeks	minimum	duration	between	samples.	It	is	important	to	note	that	the	sample	size	reduces	as	the	duration	between	samples	increases	in	the	cohort	data.	Estimation	of	the	follow-up	time	standardised	version	of	cVL	for	the	same	subsets	indicates	a	similar	tendency,	but	with	a	slightly	smaller	magnitude	of	bias	compared	to	the	non-standardised	estimates,	ranging	to	only	+9%	in	the	simulated	data	to	+299%	in	the	cohort	data	(Table	3).	
Table	3:	Estimated	cVL	using	complete	time	series	per	individual	(bold)	and	using	different	frequencies	of	observations	for	sub-samples.	Estimates	given	as	median	(IQR)	of	individual	cVL	calculations	and	as	relative	percent	change	between	median	cVL	levels.	Values	given	as	median	(Q1,	Q3)	unless	specified.	
	 Simulated	data	 Cohort	data	
	 cVLREF	 cVLFUD	 cVLREF	 cVLFUD	
Reference	cVL		(all	samples)	 2.08	(1.84,	2.72)	 2.09	(1.57,	2.24)	 0.49	(0.20,	0.97)	 	0.50	(0.23,	1.34)	4	wks	between	samples	 2.25	(1.8,	2.74)	 2.07	(1.64,	2.31)	 0.67	(0.37,	1.12)	 0.73	(0.36,	1.52)			Percent	change	from	cVLREF	 +8%	 -1%	 +36%	 +46%	8	wks	between	samples	 2.23	(1.83,	2.75)	 2.07	(1.61,	2.34)	 0.79	(0.48,	1.55)	 1.07	(0.47,	1.83)			Percent	change	from	cVLREF	 +7%	 +0%	 +62%	 +115%	12	wks	between	samples	 2.31	(1.91,	2.82)	 2.14	(1.65,	2.4)	 0.98	(0.58,	1.93)	 1.26	(0.63,	1.95)			Percent	change	from	cVLREF	 +11%	 +2%	 +100%	 +154%	
24	wks	between	samples	 2.5	(1.99,	3.02)	 2.27	(1.75,	2.61)	 2.12	(0.92,	3.09)	 1.99	(1.53,	2.48)	
		Percent	change	from	cVLREF	 +20%	 +9%	 +335%	 +299%		
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4	Discussion	Estimating	the	true	cumulative	exposure	by	approximating	the	area	under	a	curve	using	repeat	measures	of	a	biomarker	such	as	VL	on	time	scales	that	are	routine	in	clinical	care	(weeks	to	months)	is	subject	to	a	number	of	sources	of	bias.	As	the	“true”	shape	of	the	trajectory	between	measurements	is	unknown,	approximation	of	cVL	has	typically	been	by	a	crude	method	of	geometric	approximation	known	as	the	trapezoidal	rule.	In	most	empirical	work	with	repeated	measures	of	VL,	the	sparsity	of	VL	measures	over	time	ensures	that	accurate	approximation	of	the	true	trajectory	is	unlikely.	Even	within	a	single	study,	unless	VL	measures	occur	with	the	same	timing	and	frequency	for	every	individual,	the	measure	of	cVL	may	be	more	reflective	of	sampling	frequency	bias	than	any	underlying	biological	mechanism:	cVL	for	individuals	with	fewer,	or	more	widely	spaced	measures	will	be	inaccurate	and	biased	upwards	compared	to	individuals	with	more,	or	more	frequent,	VL	measures.		Estimation	of	cVL	via	the	trapezoidal	rule	has	the	potential	for	significant	bias	and	inaccuracy	depending	on	the	frequency	of	VL	measures	and	underlying	stochastic	process.	In	populations	with	moderate	to	high	rates	of	partial	or	non-adherence,	long	periods	between	observations	may	result	in	inaccuracy	with	respect	to	estimation	of	the	time	an	individual	spends	with	elevated	VL.	Similarly,	different	frequencies	of	observation	have	a	clear	impact	on	estimated	cumulative	viremia	and	tend	to,	if	anything,	overestimate	the	exposure.	Cumulative	VL	may	be	a	useful	indicator	for	relative	exposure	within	studies	if	individuals	have	been	subject	to	similar	frequency	and	timing	of	viral	load	measures.	Comparison	of	cVL	between	data	sets	or	studies	are	best	undertaken	with	a	great	deal	of	caution,	as	variation	in	observation	frequency	or	timing	invalidates	comparison	of	the	relative	measure.	While	relative	measures	of	exposure,	for	example,	pack-years	in	smoking	exposure,	are	routinely	compared	across	studies,	it	is	necessary	to	do	so	with	an	assumption	that	the	underlying	exposure	is	not	changing	substantially	over	time,	though	this	is	rarely	stated.		Some	approaches	to	reducing	the	impact	of	sampling	bias	have	been	applied.	Mugavero	et	al.	[4]	use	inverse	weights	to	adjust	for	sampling	frequency,	resulting	in	a	positive	association	between	cVL	and	mortality	outcomes.	However,	this	approach	is	only	applicable	in	the	case	where	a	reasonable	approach	to	estimation	of	the	inverse	weights	is	possible.	Other	integral	estimation	methods	are	available,	for	example,	composite	Simpson’s	rule	[17]	which	uses	a	third	order	polynomial	to	interpolate	between	successive	points,	and	is	know	to	be	more	accurate	than	trapezoidal	estimation	[17],	but	requires	evenly	spaced	time	points	which	are	uncommon	in	most	cohort	studies.	Another	approach	may	be	to	avoid	attempts	at	cumulative	viraemia	exposures	altogether	in	favour	of	simpler	measures	which	may	be	more	directly	interpretable	[22].	Finally,	we	note	that	the	use	of	the	term	cumulative	viremia	or	viral-copy-years	is	non-
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precise,	as	different	researchers	have	utilised	slightly	different	definitions,	both	in	terms	of	using	copies/mL	vs	log10	copies/mL,	different	handling	of	VL	measures	below	the	limit	of	detection	and	different	methods	of	follow-up	duration	standardisation.	The	key	point	here	is	that	without	standardisation	of	the	estimate,	and	without	an	explicit	process	for	managing	sampling	frequency	and	other	sources	of	obvious	bias,	the	measures	of	cumulative	exposure	to	raised	HIV	viral	load	cannot	be	presumed	consistent	and	are	unlikely	to	be	comparable	across	studies.		In	summary,	cVL	exposure	estimates	should	be	used	with	caution	as	they	will	tend	to	overestimate	the	true	exposure	to	raised	viremia,	and	should	not	be	used	as	an	absolute	measure	of	comparison	between	studies	or	cohorts	with	different	frequencies	of	VL	monitoring.	Utilisation	of	cVL	as	a	relative	measure	within	a	well	characterised	and	consistently	observed	cohort	may	provide	useful	relative	estimates	of	differential	exposure	to	raised	viral	load	over	time.																	
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